Clinical Trial

Propionic Acid for Multiple Sclerosis: Safety and Benefits

Name: Propionic Acid for Multiple Sclerosis: Safety and Benefits — clinical trial record (NCT07595081)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Pro-MADAI

Completed Phase 2/3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).

Trial Details

NCT Number	NCT07595081
Lead Sponsor	Salzburger Landeskliniken
Conditions	Multiple Sclerosis
Enrollment	22 participants
Start Date	2024-08-01
Primary Completion	2025-05-01 (estimated)
Study Completion	2025-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-19